First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis.
<h4>Background</h4>It remains unknown which is the optimal first-line treatment regimen for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We performed a network meta-analysis to address this important issue.<h4>Methods<...
Saved in:
Main Authors: | Hongwei Zhang, Jun Chen, Tingting Liu, Jun Dang, Guang Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0223530&type=printable |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of first-line afatinib in older patients with advanced EGFR-mutated non-small cell lung cancer
by: Mi-Hyun Kim, et al.
Published: (2025-07-01) -
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01) -
First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01) -
Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
by: O. N. Pavlova, et al.
Published: (2024-04-01) -
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
by: Tingting Liu, et al.
Published: (2023-01-01)